HK1220896A1 - 拮抗劑治療阿爾茲海默症的方法 - Google Patents
拮抗劑治療阿爾茲海默症的方法Info
- Publication number
- HK1220896A1 HK1220896A1 HK16108924.6A HK16108924A HK1220896A1 HK 1220896 A1 HK1220896 A1 HK 1220896A1 HK 16108924 A HK16108924 A HK 16108924A HK 1220896 A1 HK1220896 A1 HK 1220896A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antagonists
- methods
- alzheimers disease
- treat alzheimers
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361829713P | 2013-05-31 | 2013-05-31 | |
PCT/US2014/040160 WO2014194166A1 (en) | 2013-05-31 | 2014-05-30 | Methods of using il-1 antagonists to treat alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1220896A1 true HK1220896A1 (zh) | 2017-05-19 |
Family
ID=51023151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16108924.6A HK1220896A1 (zh) | 2013-05-31 | 2016-07-26 | 拮抗劑治療阿爾茲海默症的方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160120941A1 (zh) |
EP (1) | EP3003356B1 (zh) |
JP (2) | JP2016520615A (zh) |
AU (1) | AU2014274044B2 (zh) |
CA (1) | CA2911547A1 (zh) |
HK (1) | HK1220896A1 (zh) |
WO (1) | WO2014194166A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019002673A (es) * | 2016-09-12 | 2019-07-04 | Hoffman Steven | Composiciones y metodos para tratar demencia. |
US11248054B2 (en) | 2017-06-12 | 2022-02-15 | Bluefin Biomedicine, Inc. | Anti-IL1RAP antibodies and antibody drug conjugates |
CN111670032A (zh) * | 2018-01-31 | 2020-09-15 | 欧拉泰克治疗有限责任公司 | 预防或治疗阿尔茨海默氏病的方法 |
CN111956933B (zh) * | 2020-08-27 | 2022-05-03 | 北京理工大学 | 一种阿尔兹海默病神经反馈康复系统 |
WO2022167916A1 (en) * | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
KR20230109107A (ko) * | 2022-01-10 | 2023-07-19 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965421A (en) * | 1997-11-26 | 1999-10-12 | Human Genome Sciences, Inc. | Human IRAK-2 |
US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US7629311B2 (en) * | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
CA2450809A1 (en) * | 2001-06-15 | 2002-12-27 | Interleukin Genetics, Inc. | Methods for detecting and treating the early onset of aging-related conditions |
US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
US20050129685A1 (en) * | 2003-09-18 | 2005-06-16 | Jingtai Cao | Use of IL-1 blockers to prevent corneal inflammation and neovascularization |
US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
MXPA06014126A (es) * | 2004-06-04 | 2007-07-18 | Regeneron Pharma | Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias. |
JP2008523815A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
DE602006010072D1 (de) * | 2005-06-21 | 2009-12-10 | Chen Gang | Il-1 bindende antikörper und fragmente davon |
US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
EP2337799A2 (en) * | 2008-08-28 | 2011-06-29 | Wyeth LLC | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
DK2558577T3 (en) * | 2010-04-16 | 2019-04-01 | Nuevolution As | Bi-functional complexes and methods for the preparation and use of such complexes |
HUE063115T2 (hu) * | 2010-07-29 | 2023-12-28 | Buzzard Pharmaceuticals AB | Kiméra I-es típusú IL-1 receptor antagonisták |
CN103476933B (zh) * | 2011-03-14 | 2016-04-13 | 弗洛格有限公司 | 白介素1受体的拮抗剂 |
-
2014
- 2014-05-30 WO PCT/US2014/040160 patent/WO2014194166A1/en active Application Filing
- 2014-05-30 CA CA2911547A patent/CA2911547A1/en not_active Abandoned
- 2014-05-30 US US14/893,932 patent/US20160120941A1/en not_active Abandoned
- 2014-05-30 AU AU2014274044A patent/AU2014274044B2/en not_active Ceased
- 2014-05-30 JP JP2016517030A patent/JP2016520615A/ja active Pending
- 2014-05-30 EP EP14733888.3A patent/EP3003356B1/en active Active
-
2016
- 2016-07-26 HK HK16108924.6A patent/HK1220896A1/zh unknown
-
2018
- 2018-04-12 JP JP2018076729A patent/JP2018111723A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2911547A1 (en) | 2014-12-04 |
AU2014274044A1 (en) | 2016-01-21 |
JP2018111723A (ja) | 2018-07-19 |
EP3003356B1 (en) | 2019-07-03 |
JP2016520615A (ja) | 2016-07-14 |
US20160120941A1 (en) | 2016-05-05 |
AU2014274044B2 (en) | 2019-06-27 |
WO2014194166A1 (en) | 2014-12-04 |
EP3003356A1 (en) | 2016-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
HK1220980A1 (zh) | 用於治療龐貝氏症的方法和組合物 | |
EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
EP2970317A4 (en) | PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES | |
BR302013004392S1 (pt) | Configuração aplicada emmetal sanitário | |
EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
GB201322094D0 (en) | Methods and compositions relating to alzheimers disease | |
HK1220896A1 (zh) | 拮抗劑治療阿爾茲海默症的方法 | |
FI20135770A (fi) | Prosessi hiilivetyjen valmistamiseksi | |
GB201403997D0 (en) | Methods and sustems related to electrosurgical wands | |
BR112015001724A2 (pt) | métodos de tratamento de condições relacionadas a fgfr3 | |
ZA201507771B (en) | Compounds and methods to isolate gold | |
HK1219653A1 (zh) | 治療線粒體疾病的方法 | |
GB2517174B (en) | Assessment of structural health | |
IL244453A0 (en) | Methods for determining response to medical treatment | |
EP2950779A4 (en) | METHODS OF LAUNDERING THE SKIN BY USING CANOLA EXTRACTS | |
DK2988659T3 (da) | Forbedrede fremgangsmåder til vævskarakterisering | |
SG11201506805QA (en) | Organic compositions to treat epas1-related diseases | |
PL2875736T3 (pl) | N-karbamoiloputrescyna do zwiększenia syntezy białka mięśni | |
ZA202207530B (en) | Use of phenoxypropylamine compounds to treat depression | |
HK1214964A1 (zh) | 製備包含治療性蛋白質的顆粒的方法 | |
PL3079684T3 (pl) | Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna | |
HK1216150A1 (zh) | 匹多莫德治療炎症性腸病的用途 | |
HK1220133A1 (zh) | 改善微血管完整性的方法 | |
GB201321628D0 (en) | Treatment of disease |